Prof Andrew Martin
Professor of and Computational Biology
Structural & Molecular Biology
Div of Biosciences
- Joined UCL
- 1st Jan 2004
My main interests are in (1) sequence, structure and function of antibodies, (2) effects of mutation on protein structure and function, (3) protein modelling, (4) software development for Bioinformatics.
I give first year tutorials on experimental biochemistry and second year tutorials on protein structure. I give introductory bioinformatics lectures to second year students as well as lectures on protein energetics, protein folding and antibody structure. I teach extensively on the third year bioinformatics module and on the Birkbeck/UCL Bioinformatics MSc. I teach bioinformatics for drug design, antibody structure and patent issues on the MSc in drug design. I am also coordinator for Transitions and Peer Assisted Learning in the department and teach session on programming and on patents and intellectual property as part of core modules.
- University of Oxford
- DPhil, Biochemistry | 1990
- University of Oxford
- BA Hons, Biochemistry | 1986
I obtained my first degree in Biochemistry from Christ Church, Oxford where I did my research project with Peter Goodford working on his GRID program - one of the first methods for computational drug design; this inspired my interest in computational biology and bioinformatics. I stayed in Oxford to do my D.Phil with Tony Rees and developed the first automated program for modelling antibodies. This was later commercialized by Oxford Molecular (OML).
After a brief stint with Willie Taylor at NIMR, I became self-employed, helping OML with commercialization of my software, and writing other scientific software including for the National Grid Company and Bradwell Nuclear Power Station. I then spent two months working at the DKfz in Heidelberg before joining Janet Thornton's group at UCL. I then became a temporary lecturer at UCL seconded 4 days a week to a spinout company, Inpharmatica, before moving to the University of Reading as a lecturer in 1999 and returning to UCL in 2004.
I have acted as a consultant to pharmaceutical companies and as an advisor or expert witness in several patent disputes. In 2016 I joined the World Health Organization International Nonproprietary Names committee as an advisor on naming and annotation of antibody-based drugs.